ProCE Banner Activity

Selecting Second-line Treatment After Atezolizumab Plus Bevacizumab for Patients With Advanced HCC

Clinical Thought
With atezolizumab plus bevacizumab becoming a standard of care for first-line systemic treatment of patients with advanced HCC, second-line therapy for these patients has become more challenging. In this commentary, expert faculty discuss treatment options in this setting.

Released: October 01, 2020

Expiration: September 30, 2021

No longer available for credit.

Share

Faculty

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Amit G. Singal

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Lilly

Faculty Disclosure

Primary Author

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Lipika Goyal, MD, MPhil, has disclosed that she has received consulting fees from Agios, Alentis, AstraZeneca, Debiopharm, H3 Biomedicine, Incyte, QED Therapeutics, Sirtex, and Taiho.

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Genentech/Roche, Glycotest, GRAIL, Merck, and Wako.